The problem is this: the bulk of the improvement in human health on the population scale to date can be attributed to public health measures. This is why low cost treatments often seem as good or nearly as effective as expensive ones. However, regenerative medicine offers a qualitatively higher level of medical care. If indeed it constitutes a potential breakthrough, or if some other advance in biotechnology does, the old cost/benefit analyses will need to be considerably updated.